Evidence map›Paper›PMID 41588972›Full record

ArticleCurrent drug metabolism2026

Computational Chemistry Approach in the Assessment of Potential Acyl Glucuronide-mediated Toxicity.

Nathan D Ricke, Markus Walles, Russell Jones, John Davis, Mithat Gunduz

Abstract read
PubMed Publisher
In one paragraph

Article in Current drug metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Nathan D RickeDepartment of Global Discovery Chemistry, Novartis BioMedical Research, Inc., Cambridge, MA, US.ORCID 0000-0003-3815-6230
Markus WallesDepartment of Pharmacokinetic Sciences, Global Biotransformation, Novartis Biomedical Research, Inc., Basel, Switzerland.
Russell JonesDepartment of Pharmacokinetic Sciences, Global Biotransformation, Novartis Biomedical Research, Inc., Basel, Switzerland.
John DavisDepartment of Pharmacokinetic Sciences, Global Biotransformation, Novartis Biomedical Research, Inc., Cambridge, MA, US.
Mithat GunduzDepartment of Pharmacokinetic Sciences, Global Biotransformation, Novartis Biomedical Research, Inc., Cambridge, MA, US.ORCID 0009-0002-1495-1408

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAcyl glucuronides are common phase II metabolites of xenobiotics and can sometimes contribute to idiosyncratic toxicities. Their reactivity is primarily mediated through acyl migration and/or nucleophilic displacement, and shorter acyl glucuronide halflives are associated with increased reactivity. This reactivity can lead to metabolite-induced toxicity, posing a significant risk during drug development.

methodsWe developed regression models trained on features derived from Density Functional Theory (DFT) calculations to predict the half-lives of acyl glucuronide metabolites. The aim was to provide a computational tool to guide the design of drug candidates with more stable acyl glucuronide metabolites.

resultsThe best-performing model achieved a strong correlation between predicted and experimental half-lives, with an R² of 0.67 on the test set. Predicted half-lives for drugs classified as clinically safe were longer than those for drugs in the warning and withdrawn categories, demonstrating a separation comparable to experimentally measured half-lives. DISCUSSION: The model is sufficiently accurate to support the optimization of acyl glucuronides for longer half-lives. Further analysis indicated that acyl glucuronide stability can be modulated by electron-donating and electron-withdrawing groups, effects that are effectively captured by the model.

conclusionThis modeling approach can be applied during drug discovery to reduce the risk of metabolite-related toxicity by enabling in silico screening of compound modifications and ranking them based on predicted effects on acyl glucuronide half-life.

Indexed as

GlucuronidesXenobioticsComputational ChemistryDensity Functional TheoryHalf-LifeHumansGlucuronidesXenobioticsacyl glucuronidesbioactivationglucuronidationin silicoreactivitystabilitythioacyl glutathioneUGT

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.